Pfizer Inc. (PFE)
US FDA approves Pfizer's bleeding disorder drug for children
The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of bleeding episodes in children and in certain patients with hemophilia, the company said on Monday.
3 Dividend Stocks to Buy Hand Over Fist in June
Pfizer has a rich pipeline of drugs in development, at least some of which are likely to sell well. UPS has turned away from Amazon.com and toward more profitable deliveries.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nordisk's weekly injection Wegovy.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
L
Pfizer vs Merck: Chasing High Yield vs Higher Returns
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) both just closed earnings chapters that frame the 2026 dividend debate clearly.
Pfizer's Obesity and Oncology Pipeline Sets Up a Catalyst-Rich 2026
PFE targets a catalyst-rich 2026 with pivotal obesity and oncology studies, key data readouts, and regulatory decisions across its pipeline.
Why Pfizer's Current Price May Be Too Cheap to Ignore
Pfizer (NYSE:PFE | PFE Price Prediction) is one of those names where the headline narrative (COVID hangover, patent cliff) keeps overshadowing what is actually a defensive cash machine trading at a single-digit forward multiple.
Here is What to Know Beyond Why Pfizer Inc. (PFE) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.
Mailbag: A Follow-Up on Pfizer & Other Questions
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
Innovent Biologics shares rise 10% after pact with Pfizer of up to $10.5 billion
The partnership includes licensing, co-development, and co-commercialization opportunities across a diverse portfolio of antibody-drug conjugates. Innovent will will co-commercialize with Pfizer in the U.S. and Europe and share profits but retain rights in the Greater China market.
Insiders Aren't Buying Pfizer Stock at $26 and That's Actually a Good Thing
The smart money on Pfizer (NYSE: PFE | PFE Price Prediction) is sending a quieter signal than the financial press typically rewards: institutional analysts are constructive, insiders are not transacting in size in either direction, and the dividend yield is doing the heavy lifting.
Pfizer Bets on New & Acquired Drugs to Offset Its LOE Pressure?
PFE is banking on new launches, Seagen assets and pipeline progress to counter a looming patent cliff through 2030.
